BIOGEN INC. (BIIB) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | (m) | Operating Income (Loss) |
| Revenue | 9.94B USD | |
| Cost of products and services | 2.44B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 2.47B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $9.94B | $2.44B | (m) | $2.47B | (m) |
| 2025-12-31 | (m) | $9.89B | $2.40B | (m) | $2.43B | (m) |
| 2025-09-30 | (m) | $10.07B | $2.49B | (m) | $2.43B | (m) |
| 2025-06-30 | (m) | $10.00B | $2.46B | (m) | $2.42B | (m) |
| 2025-03-31 | (m) | $9.82B | $2.40B | (m) | $2.39B | (m) |
| 2024-12-31 | (m) | $9.68B | $2.31B | (m) | $2.40B | (m) |
| 2024-09-30 | (m) | $9.61B | $2.35B | (m) | $2.33B | (m) |
| 2024-06-30 | (m) | $9.67B | $2.37B | (m) | $2.53B | (m) |
| 2024-03-31 | (m) | $9.66B | $2.41B | (m) | $2.53B | (m) |
| 2023-12-31 | (m) | $9.84B | $2.53B | (m) | $2.55B | (m) |
| 2023-09-30 | (m) | $9.99B | $2.49B | (m) | $2.57B | (m) |
| 2023-06-30 | (m) | $9.97B | $2.30B | (m) | $2.35B | (m) |
| 2023-03-31 | (m) | $10.10B | $2.19B | (m) | $2.37B | (m) |
| 2022-12-31 | (m) | $10.17B | $2.28B | (m) | $2.40B | (m) |
| 2022-09-30 | (m) | $10.36B | $2.37B | (m) | $2.56B | (m) |
| 2022-06-30 | (m) | $10.63B | $2.41B | (m) | $2.65B | (m) |
| 2022-03-31 | $2.48B | $10.82B | $2.39B | (m) | $2.71B | 22.90% |
| 2021-12-31 | $2.84B | $10.98B | $2.11B | (m) | $2.67B | 25.87% |
| 2021-09-30 | $1.92B | $11.10B | $1.94B | (m) | $2.69B | 17.32% |
| 2021-06-30 | $2.22B | $11.70B | $1.88B | (m) | $2.61B | 18.94% |
| 2021-03-31 | $3.70B | $12.60B | $1.83B | (m) | $2.53B | 29.39% |
| 2020-12-31 | $4.55B | $13.44B | $1.81B | (m) | $2.50B | 33.84% |
| 2020-09-30 | $6.66B | $14.26B | $1.76B | (m) | $2.36B | 46.68% |
| 2020-06-30 | $7.38B | $14.49B | $1.74B | (m) | $2.34B | 50.93% |
| 2020-03-31 | $7.36B | $14.42B | $1.81B | (m) | $2.38B | 51.03% |
| 2019-12-31 | $7.04B | $14.38B | $1.96B | (m) | $2.37B | 48.98% |
| 2019-09-30 | $6.71B | $14.23B | $2.00B | (m) | $2.30B | 47.13% |
| 2019-06-30 | $6.60B | $14.07B | $2.03B | (m) | $2.24B | 46.90% |
| 2019-03-31 | $5.86B | $13.81B | $1.97B | (m) | $2.17B | 42.40% |
| 2018-12-31 | $5.89B | $13.45B | $1.82B | (m) | $2.11B | 43.77% |
| 2018-09-30 | $5.91B | $13.23B | (m) | (m) | $2.09B | 44.66% |
| 2018-06-30 | $5.87B | $12.87B | (m) | (m) | $2.02B | 45.57% |
| 2018-03-31 | $5.85B | $12.59B | (m) | (m) | $1.94B | 46.48% |
| 2017-12-31 | $5.34B | $12.27B | (m) | (m) | $1.94B | 43.54% |
| 2017-09-30 | $4.76B | $11.84B | (m) | (m) | $1.86B | 40.25% |
| 2017-06-30 | $4.54B | $11.72B | (m) | (m) | $1.89B | 38.72% |
| 2017-03-31 | $4.80B | $11.53B | (m) | (m) | $1.95B | 41.59% |
| 2016-12-31 | $5.15B | $11.45B | (m) | (m) | $1.95B | 44.99% |
| 2016-09-30 | $5.43B | $11.42B | (m) | (m) | $2.04B | 47.59% |
| 2016-06-30 | $5.38B | $11.24B | (m) | (m) | $2.05B | 47.86% |
| 2016-03-31 | $5.15B | $10.94B | (m) | (m) | $2.05B | 47.11% |
| 2015-12-31 | $4.89B | $10.76B | (m) | (m) | $2.11B | 45.44% |
| 2015-09-30 | $4.88B | $10.57B | (m) | (m) | $2.10B | 46.21% |
| 2015-06-30 | $4.66B | $10.30B | (m) | (m) | $2.20B | 45.28% |
| 2015-03-31 | $4.42B | $10.13B | (m) | (m) | $2.28B | 43.63% |
| 2014-12-31 | $3.97B | $9.70B | (m) | (m) | $2.23B | 40.94% |
| 2014-09-30 | $3.47B | $9.03B | (m) | (m) | $2.18B | 38.44% |
| 2014-06-30 | $3.00B | $8.34B | (m) | (m) | $2.02B | 35.98% |
| 2014-03-31 | $2.68B | $7.65B | (m) | (m) | $1.87B | 35.00% |
| 2013-12-31 | $2.52B | $6.93B | (m) | (m) | $1.71B | 36.29% |
| 2013-09-30 | $2.30B | $6.38B | (m) | (m) | $1.57B | 36.07% |
| 2013-06-30 | $2.15B | $5.94B | (m) | (m) | $1.46B | 36.25% |
| 2013-03-31 | $2.00B | $5.64B | (m) | $1.26B | $1.33B | 35.41% |
| 2012-12-31 | $1.86B | $5.52B | (m) | $1.33B | $1.28B | 33.64% |
| 2012-09-30 | $1.82B | $5.43B | (m) | $1.33B | $1.19B | 33.54% |
| 2012-06-30 | $1.77B | $5.35B | (m) | $1.33B | $1.15B | 33.14% |
| 2012-03-31 | $1.68B | $5.14B | (m) | $1.28B | $1.11B | 32.66% |
| 2011-12-31 | $1.72B | $5.05B | (m) | $1.22B | $1.06B | 34.16% |
| 2011-09-30 | $1.67B | $4.94B | (m) | $1.17B | $1.05B | 33.81% |
| 2011-06-30 | $1.38B | $4.81B | (m) | $1.19B | $1.03B | 28.63% |
| 2011-03-31 | $1.36B | $4.81B | (m) | $1.24B | $1.03B | 28.30% |
| 2010-12-31 | $1.25B | $4.72B | (m) | $1.25B | $1.03B | 26.48% |
| 2010-09-30 | $1.28B | $4.62B | (m) | $1.24B | $996.77M | 27.62% |
| 2010-06-30 | $1.47B | $4.57B | (m) | $1.23B | $979.36M | 32.11% |
| 2010-03-31 | $1.29B | $4.45B | (m) | $1.31B | $937.87M | 29.08% |
| 2009-12-31 | $1.30B | $4.38B | (m) | $1.28B | $911.03M | 29.59% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $1.21B | $4.10B | (m) | $1.07B | $925.30M | 29.62% |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $779.77M | $3.17B | (m) | $925.16M | $776.10M | 24.59% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |